Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07743008 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Phase 2 Trial of a Haemophilus Influenzae Serotype a (Hia) Glycoconjugate Vaccine

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
This study is testing a vaccine designed to protect against Haemophilus influenzae type a (Hia), a bacterium that can cause serious infections.This is a phase 2 trial. The study will include healthy adults between the ages of 18 and 65. Participants will be randomly assigned to receive either the Hia vaccine or a placebo. The main goals of the study are to determine safety and measure immune response as it relates to protection against Hia.
Trial Details
NCT Number NCT07743008
Lead Sponsor InventVacc Biologicals Inc.
Collaborators: McGill University Health Centre/Research Institute of the McGill University Health Centre, Dalhousie University, Canadian Center for Vaccinology, Canadian Immunization Research Network
Conditions
(from sponsor)		 Haemophilus Influenzae, Haemophilus Influenzae Type a
Related terms Haemophilus Infections
Enrollment 47 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov